At the the end of the day this message is simply a free forum for people. a few of the posts are relevant but a lot of the posts are simply intended to insult and/or amuse.
The company is advancing on all fronts. While everything has not developed as quickly or perfectly as some would like, one needs to consider the minor nature of the setbacks in Iclusig approvals in their proper context.
While the setbacks in labeling will probably effect Iclusig sales short term, eventually the EPIC trial will in all probability demonstrate Iclusig is best in class. The drug should also gain approval as best in class for additional indications. AP 26113 will be advancing and next year the company will be revealing a new molecule that might not be a TKI.
I think the argument for investing in this company is still very compelling.
Best regards to all my fellow long time investors.
I am fairly sure Royal will come back with a better offer.
We now have the company in competition with the suitor for the shareholders favor. Of course there is the possibility Elan's refusal to engage Royal, the Dutch Auction, and the cash dividend are simply tactics to drive the price of the buyout higher.
Royal first approached Elan in August. I think KM is a lousy biotech CEO in many respects but I believe he knows how to play poker.